OnKure Therapeutics (OKUR) Preferred Stock Liabilities (2020 - 2023)

OnKure Therapeutics (OKUR) has reported Preferred Stock Liabilities for 3 consecutive years, with $129.8 million the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $129.8 million; the trailing twelve-month figure through Dec 2023 stood at $129.8 million (changed N/A YoY), and the FY2023 full-year result was $129.8 million, changed N/A from the prior year.
• Preferred Stock Liabilities grew to $129.8 million in Q4 2023 per OKUR's latest filing, from $94.4 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $129.8 million in Q4 2023 and bottomed at $45.7 million in Q1 2020.
• Historically, Preferred Stock Liabilities has averaged $68.0 million across 3 years, with a median of $46.4 million in 2020.
• The widest YoY moves for Preferred Stock Liabilities: up 106.83% in 2021, down 106.83% in 2021.
• Over 3 years, Preferred Stock Liabilities stood at $47.1 million in 2020, then soared by 100.61% to $94.4 million in 2021, then soared by 37.49% to $129.8 million in 2023.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $129.8 million, $94.4 million, and $47.1 million for Q4 2023, Q1 2021, and Q4 2020 respectively.